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Human hypersensitivity angiitis is an immune com-
plex disease in which patients present with palpable 
purpuric lesions of the skin and may often have multiple 
organ involvement. The antigen may be derived from 
an infectious organism such as the hepatitis virus, strep-
tococcus, or a drug, and complexes with antibody. Under 
circumstances of vascular turbulence or vessel wall dil-
atation this complex may become fixed, activating the 
complement sequence with elaboration of chemotactic 
factors for neutrophils. These cells release lysosomal 
enzymes resulting in vessel wall destruction. Red blood 
cells leak into the tissue producing purpura and the 
inflammatory infiltrate accounts for the palpability. Al-
though many patients have skin lesions only, others may 
have involvement of joints, gastrointestin~l tract, kid-
neys, and even the lungs. 
The central question in the pathogenesis of this disease 
is why the immune complex is so selective in its site of 
deposition. Part of the reason must be related to the 
lattice formation of a particular complex, while other 
reasons are related to host factors of altered vascular 
permeability, integrity of clearance mechanisms or even 
a genetically determined defect of the phagocytic sys-
tem. 
Hypersensitivity angiitis is a term used to describe a well-
recognized clinico-pathologic entity of palpable purpuric lesions 
of the skin seen clinically and small vessel wall destruction 
seen histologically. Confusion sometimes develops because of 
the variety of names used to describe the same disease and 
include: allergic vasculitis, leukocytoclastic vasculitis, necrotiz-
ing vasculitis, and Henoch-Schi:ienlein Purpura. Several clinical 
observations and experimental studies lend strong support to 
an immune complex mechanism for development of lesions. 
However, there are some critical unanswered questions. It is 
the purpose of this review to examine the evidence and explore 
the questions. 
HYPERSENSITIVITY ANGIITIS AS A CLINICAL 
DISEASE 
Patients usually present with the acute onset of palpable 
purpuric lesions on the lower legs (Fig 1). The presence of 
palpability immediately sets this process apart from the large 
group of conditions which are responsible for cutaneous pur-
pura that is not elevated above the surface of the skin. The 
palpability implies an in!1ammatory process. As might be ex-
pected, lesions are not necessarily limited to the skin and may 
involve vessels in other organs, especially the kidneys, joints, 
gastrointestinal tract, and lungs. What is surprising, however, 
is that many patients may have lesions only in the skin and 
they may persist there recurrently for months or years without 
ever involving vessels in any other organ. Possible reasons for 
this will be considered later in this review. In other patients, 
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identical clinical and pathologic lesions may occur in associa-
tion with such diseases as systemic lupus erythematosus (LE), 
essential mixed cryoglobulinemia, and autoimmune hemolytic 
anemia. Also noteworthy, in light of the discussion to follow, is 
that similar histopathologic findings may be seen in specific 
larger vessels and organs leading to such entities as polyarteritis 
nodosa and Wegener's granulomatosus. As a full consideration 
of the clinical aspects of these diseases is beyond the intent of 
the present discussion the interested reader may wish to consult 
Price and Sams [1], Sams [2], or Fauci, Haynes, and Katz (3]. 
EVIDENCE FOR IMMUNE COMPLEXES IN THE 
PATHOGENESIS OF HUMAN VASCULITIS 
The currently accepted hypothesis is that hypersensitivity 
angiitis is an immune complex disease [1 - 4] (Fig 2). The 
hypothesis states that circulating complexes composed of sol-
uble antigen bound to antibody deposit within blood vessel 
walls, binding and activating complement. Complement chem-
otactic factors attract neutrophils which release lysosomal en-
zymes, causing compromised vessel function leading to hem-
orrhage. The observations and experimental evidence in hu-
mans to support the hypothesis are compelling and each will 
be discussed individually. 
Neutrophilic Infiltrate 
An inflammatory infiltrate composed of neutrophils is char-
acteristic of immune complex diseases and is the dominant 
histopathologic feature in patients with hypersensitivity vas-
culitis [5] (Fig 3). These cells are found within and around the 
vessel walls and rapidly fragment-forming "nuclear dust" or 
leukocytoclasis. In addition, as the process advances there is 
loss of integrity of the vessel wall and deposition of fibrin . The 
sequences of this dynamic process will be discussed subse-
quently. 
Granular Jmmunoreactants 
Granular deposits of immunoglobulin and complement com-
ponents are regularly observed in the vessel walls [6] (Fig 4) , a 
characteristic of immune complex-mediated disease. Comple-
ment (particularly C3) may be the only immunoreactant de-
monstrable (possibly due to its greater sensitivity) and may be 
found even in clinically uninvolved skin (7]. This latter obser-
vation is particularly intriguing since it implies that either 
larger amounts of complement, or some other factors, are 
necessary before neutrophils are attracted. 
Anticomplementary Activity of Sera 
A number of years ago Cream [8] demonstrated that sera 
from some patients with vasculitis would prevent added com-
plement from hemolysing sensitized sheep erythrocytes, imply-
ing that a substance, presumably an antigen-antibody complex, 
had bound complement so it was not available to react with the 
cells. Similar studies in larger groups of patients have confirmed 
these findings [9]. Similarly, presence of detectable levels of 
cryoglobulins has been thought to be presumptive evidence for 
presence of circulating immune complexes [9,10]. Obviously, 
findings such as these address neither the nature of the antigen 
nor antibody, or whether it is these same circulating complexes 
which become bound to tissue. 
144s 
July 1985 
F IG 1. Palpable purpuric lesions as they commonly appear on the 
lower legs. The palpabili ty implies an inflammatory process. 
I. SOLUBLE AG·AB 
COMPLEXES 
,, 
F IG 2 . The immune complex pathogenesis of vasculi tis (see text) . 
F IG 3. Histopathology reveals neutrophils within and around the 
vessel wall , thickening of the wall , fibrinoid deposition, and hemor· 
rhage. 
Presence of Hypocomplementemia 
T he presence of depressed serum complement levels usually 
suggests binding by immune complexes. In patients wi th cuta· 
neous allergic vascu li t is in association with a systemic disease 
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such as LE or severe rheumatoid arthri t is, t he serum comple-
ment levels are frequent ly low (10) . However , patients with 
cutaneous a llergic vasculit is without systemic disease usually, 
alt hough not invariably, have normal serum complement levels 
[11 ,12). T his normal complement level should not be unex· 
pected since it p resumably reflects t he relat ively small number 
of vessels involved-too few to depress total serum comple-
ment. 
Detection of Circulating Immune Complexes 
T he development of sensit ive methods to measure circulating 
immune complexes provided further opportuni ty to consider 
cutaneous vasculitis an immune complex disease. One of t he 
more commonly employed methods is t he Clq binding assay in 
which Clq labelled wit h 12"51 is added to test and control sera, 
incubated, polyethylene glycol added to separate free from 
bound Clq and radioactivity measured, t hus providing a sensi· 
t ive assay fo r detection of ant igen-ant ibody complexes capable 
of binding complement. 
Although most authors p lace great importance on t he signif-
icance of such studies in relationship to t he pathogenesis of the 
disease t he crit ical obse rver will readily recognize t hat it is not 
complexes in t he serum which causes disease-the complexes 
must fi rst fix to t issue. It is further recognized t hat immune 
complexes fo rm frequently in healt hy individuals but are 
cleared rapidly. Nevertheless, unless complexes are first formed 
in the serum t hey cannot be deposited, wit h t he except ion of 
those which may occasionally form in sit u. T hus, t he demon -
stration of elevated levels of immune complexes in t he serum 
of patients with active vasculi t is is presumpt ive evidence t hat 
t hey may be playing a role in t he pathogenesis of the disease 
[11 ,12). 
It is also possible that immune complexes may deposit in the 
vessels so rapidly after formation t hat t hey do not reach de -
tectable levels in the serum, which would help explain t hose 
patients with active vasculit is and normal immune complex 
levels. 
Histamine Trap Test 
Rationally it would seem that t he most convincing experi · 
ments to corroborate an immune complex pathogenesis for 
vasculitis would be one in which complexes could be made to 
deposit on cue and the sequence of events leading to full lesion 
expression could be examined. Braverman and Yen (13) per· 
formed t he first such experiments in which t hey injected his· 
tamine int radermally in 16 patients with active vasculit is and 
biopsied t he site at 3-4 h post injection . T heir electron micro· 
scopic observations of those sites revealed clumps of electron 
dense deposits between endothelial cells and pericytes wit hin 
the basement membrane of postcapillary venules. Neutrophils 
FIG 4. Immunofluorescence demonstrates granular deposition of 
immunoglobulins and complements within the vessel walls. Biopsy of 
an active lesion stained with fluorescein -conjugated anti-C3. 
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we re a lso seen between endotheli a l ce ll s a nd within t he vascular 
wal l. In 4 of 9 biopsies studied gra nul a r deposits of immuno-
globulin and complement (C3) were found . A fur t her suggestion 
that t hese immune complexes are pathogenic was t hat they 
found immunoreactants without neutrophils in clinically nor-
ma l non injected sk in confirming the prior obse rvation of Sams 
et a l [7]. This imp lies that t hese deposits play a p rim a ry role 
a nd do not appear merely as a seco ndary event to prior t issue 
da mage. 
Gowe r et a l [14] extended t hese stud ies do ing sequentia l 
biops ies at 1, 4, 8, a nd 24 h after in t rade rm al hi stamine injection 
in 5 patients with active vasculitis. Alt hough t he t iming and 
sequence of mo nocytic and neutrophilic infiltration varied in 
the 5 patients, immunoreactants were cons istently deposited in 
large amounts in t he first hour (F igs 5, 6) accompa nied by 
either no or ve ry few inflammatory ce ll s. Over the ensuing 
hours of the study immunoreactants decreased (Fig 7) in 
amount until at 24 h only t hose within phagocytic cell s were 
vis ible. This is similar to t he rapid remova l of deposited com-
plexes in a nimals described by Cochra ne [15]. 
Thus, these two studies provide some of the most direct 
ev idence for the role of immune complexes in the pathogene. is 
of cutaneOL1S vasculi t is. 
Clearance of Complexes 
As ment ioned ea rlier , normal individua ls form immune com-
plexes and presumably clear t hem rapid ly and, since it is 
possible t hat patients with vasculi tis have a decreased ab ility 
Ftc 5. Hista min e t rap test. Biopsy of clinica lly normal control skin 
immedia te ly a fte r histamine injection. Note sma ll a moun t of gran ula r 
C:! sta inin g. 
F tG 6. Hi sta mine t.rap test. Biopsy of cli nica lly normal sk in which 
had bee n injected with hista mine 1 h previous ly. C3 is now deposited 
in huge a mount s. 
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F IG 7. Histamine trap test. Biopsy of clinically norma l skin which 
had been injected with histam ine 8 h previously. Much of t he deposited 
C3 has a lready been removed. 
to clear complexes, Dambuyant et a l [16] elected to study t he 
question. Erythrocytes from patients with vasculi t is and con-
t rols were labeled wit h "'Cr a nd disappearance rates determined 
as we ll as radioactive scans recorded over the liver and spleen. 
No patient demonstrated a decreased clearance. In cont rast, 
Frank et al [17] desc ribe a series of studies in which a decreased 
clea rance rate of IgG coated radiolabeled autologous erythro-
cytes is found in such autoimmune diseases as systemic LE and 
mixed cryoglobulinemia. H owever, patients wit h isolated cuta-
neous vascu li tis were not studied a lt hough some of t heir pa-
tients with mixed cryoglobulins had typical cuta neous vasculi-
tis. 
EXPERIMENTAL STUDIES IN ANIMALS 
Quite obviously t here a re a number of questions raised by 
t hese observations that cannot be a nswered in humans so t hat 
investigators over t he past 25 years have performed numerous 
cri tica l experiments in a variety of laborato ry animals. These 
studies up t hrough 1972 are best summarized by Cochrane and 
Kof!ler [18]. They pointed out the importance of a vasodi lator 
released from basophilic leukocytes, which , in t he rabbit model, 
caused p late lets to clump a nd to release vasoactive amines. The 
latter caused an increase in vascu lar permeabili ty, immune 
complexes entered these areas a nd became entrapped a long the 
vessel basement membrane. They noted that in complement-
depleted animals glomeru li t is would occur but arteritis would 
not unless complement was present to attract neutrophil s. Only 
if t he complex was larger than 198 in size would it deposi t . 
They a lso noted that deposited complexes persist less t han 24 
h and t hat neu t rophils in culture degrade complexes. 
It was becoming abunda nt ly clear t hat large complexes, and 
particularly t hose with extens ive lattice formation, are removed 
rapidly from the circulation by the reticulo-endot helia l (mon-
ocyte-macrophage) system, whereas AgAb~, Ag2Ab, a nd AgAb 
complexes may persist in circulation for a long t ime [18,19], 
and may then have more of an opportunity to ini t iate t issue 
damage. 
Joselow and Mannik [20] have extended these studies by 
examining complex depos it ion in mouse skin. They fo und t hat 
complexes made at 5 ti mes ant ige n excess wi t h large lattices 
depos ited, whereas t hose made at 50 ti mes a ntige n excess, 
consisting of sma ll -latticed complexes, did not locali ze in skin 
or other t issues. In add it ion , t he depo its were patchy so that 
some vessels were spared while the lip showed a high frequency 
and intensity of deposition. Th is is a nalogous to t he clinical 
discreteness of cutaneous lesions in huma ns and probably re-
fl ects individua l vessel patency or permeabili ty at t he t ime of 
high leve ls of circu lat ing complexes. 
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UNANSWERED QUESTIONS 
From t he foregoing discussion it becomes clear t hat t he 
evidence strongly implicates an immune complex pathogenesis 
fo r allergic vasculitis. But t here remain some cent ral unan-
swered questions. One question relates to immunolo"ic mech-
anisms other t han immune complex depos ition , another to the 
nature of t he antigen and a t hird to the specific t issue locali -
zation of t he complex. 
Other Possible Immunologic Mechanisms 
The observation t hat t he infil t rate is lymphocytic and mon-
ocytic rather t han neut rophilic in some biopsies of act ive lesions 
and that some patients have normal serum complement levels 
has led to speculation that ce llular immune mechanisms may 
be involved in some patients [3,21]. Tt is proposed t hat sensi-
t ized lymphocytes, upon re-exposure to spec ific ant ige n, re l ea~e 
lymphokines including migration inhibition factors. The latter 
resul ts in migration in to and accumulation of monocytes in a 
locali zed area. These cells are t rans formed in to act ivated mac-
rophages which release lysosomal enzymes capable of causin" 
vascula r damage simila r to t hat seen wit h neut rophils. Thes~ 
activated macrophages might subsequently t ransform to epi -
t heloid and mult inucleated giant cells and develop t he typical 
hi stologic appearance of granulomatous vasculi t is seen in 
W egener's granulomatosis and allergic granuloma tous vasculi -
t is. 
Unfortunately, no well -developed experimental studies have 
directly addressed t hi s possible pathomechanism so t hat no 
more than speculat ion can be offered at t hi s t ime. 
Nature of the A n.tigen 
Although the list of proposed an t igens is long [2], very few 
of t hese have been directly demonstrated. Probably t he most 
widely accepted is t he hepatitis B surface an tigen, bu t even this 
associat ion is based primarily on epidemiologic studies (22] and 
on groups of patients wi t h both di seases s imulta neously 
[23,23]. Many ant igen assoc iations a re tempora l where typical 
vasculit ic lesions follow drug or infectious exposure. For in -
stance, there are oq:asional reports, such as t hat by Lambert 
a nd colleagues (25], where a patient admini ste red t he same 
drug on two occasions developed a llergic vasculi t is. Experienced 
clinicians can relate anecdotes of patients who develop a flu -
li ke illness each winte r followed by vasculi t is, or farmers re-
peatedly exposed to insecticides who develop typica l lesions. 
Nevertheless, t his inabili ty to clearly demonst rate t he a nt i-
gen ·in patients with spontaneous disease in no way detracts 
from the experimental animal studies of injection of preformed 
known complexes, or wi th the basic principles of immune 
complex deposition as t he pathomechanism for vasculi t is. 
Specific Tissue Localization of the Complex 
, 
This is a more difficul t question to address and one t hat 
requires some knowledge of t he way in which immune com-
plexes may be formed and t he loca l facto rs t hat may cause 
deposit ion. A fundamental question is why, if both allergic 
vasculi t is and polyarte ri t is nodosa a re immune complex dis-
eases, do t he complexes in the former deposit in small postcap-
illary venules on t he legs while, in t he latter, complexes deposit 
in large muscula r vessels such as t he ao rta and rena l arteries? 
IMMUNE COMPLEXES 
T o better understand t he depos ition of immune complexes it 
is first necessa ry to have an understanding of t he nature of 
complexes, and factors a ffecting t heir depos it ion and clearance. 
Immune Complex Formation 
For a detailed discuss ion of immune complex formation t he 
reader is referred to t he lucid articles of Ba rnett et al [26] and 
Yancey and Lawley [27] . Briefl y, the s ize of t he fin al complex 
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FI G 8. Schematic of the relative roles of valency and of a nt igen-
antibody concent ration on complex solubility and size. T he complexes 
most likely to deposit in blood vessels are those wi th oligovalent 
ant igens at or near ant igen-ant ibody equivalence. See text for details. 
(Reproduced by permission from (26]. ) 
depends on both t he valence of the respective an tigen and 
ant ibody and on their relative concent rations (Fig 8) . For 
instance, an ant ige n with only a single binding site (monova-
lent) can bind only one ant ibody. An ant igen wit h 2-4 binding 
sites (oligovalent ) can bind several ant ibodies to fo rm sma ll 
soluble complexes, while an ant ige n wi th multiple sites can 
cross -link wit h ant ibodies to form a latticework. T he latte r 
eit her precipitate or form large soluble complexes depending 
on t he relative concentration of ant igen and antibody (see 
below) . Simila rly t he valence of t he ant ibody may affect t he 
latticework, as IgM has an effect ive valence of 5 while t hat of 
lgG is 2. The relative concentrat ions of ant igen and ant ibody 
is of cri t ica l importance in determining t he size of the resul t ing 
complex and may change rapidly depending on ant ige n expo-
sure and antibody production. Antigen excess produces small 
complexes with limited opportunity for cross-linking because 
all reactive s ites on the antibody are rapidly bound by an t igen. 
At ant igen-antibody equivalence the competit ion for avai lable 
binding sit es is minimal while t he opportunity for cross- linking 
is maximal so that oligovalent antigens form large soluble 
complexes and multiva lent ant igens prec ipitate. At ant ibody 
excess oligovalent ant ige ns form soluble complexes smaller 
than those fo rmed at equivalence, while mult ivalent ant igens 
precipitate. Thus, t he complexes most likely to cause lesions 
are those wi th oligovalent antigens fo rmed at or about ant igen-
antibody equiva lence. That is, t hese are t he largest complexes 
that remain soluble. 
Immune Complex Deposition 
Of course, even a la rge and soluble complex may remain in 
the circulation unless something happens to t he vessel wa ll to 
cause deposit ion. For instance, deposition may occur at sites of 
vessel bifurcation where the fl ow becomes turbulent, such as at 
the bifurcation of t he renal artery and aorta in polya rterit is 
nodosa . Deposit ion may occur on t he lower legs in allergic 
vasculitis because of t he increased hydrodynamic pressure and 
sluggish flow, accentuated by the cooler temperature of t he 
skin. Possibly this explains why lesions may occur recurrent ly 
on the legs without involvement of any internal organ. 
An increase in vascular permeability appears likely to resul t 
in deposit ion of complexes and is likely due to vasoactive 
amines released from platelets and lgE triggered basop hils 
[18,28]. Important ly, t he histamine t rap test discussed previ-
ously provides direct evidence t hat vasodilation , by whatever 
means, will likely cause circulating complexes to depos it . 
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Immune Complex Clearance 
A third factor which would like ly a ffect depos ition of large 
soluble complexes is t heir rate of cleara nce. Obvious ly, a com-
p lex wh ic h ci rculates for some time has a greater chance to 
deposit t ha n one that is cleared ra pidly . Al t hough this question 
h as been addressed as discussed previous ly, those studies may 
not be quite a pplicable because the investigators examined 
clearance of labeled erythrocytes rather than immune com-
p lexes. 
Another factor which may affect cleara nce is that the mon-
ocyte-phagocytic system may become saturated by an over-
whelming a m ount of complexes a nd be physically unable to 
remove any more [29 ). 
In summa ry, then, the spec ific tissue localization of a circu-
latin g immune complex is dete rmined by a series of highly 
va riab le factors. That one of these facto rs is not t he antigen 
itse lf is made clea r by t he wide qua litative and quantitative 
spectrum o f disease expression in patie nts with hepatitis B 
a n t igen emia-associated vasculit is [30) . Much more likely is the 
nature of t he individual complex a nd its interaction with an 
individua l host response and its immunoregulatory mechanism, 
integrity of the monocyte -phagocytic clearing mechanisms, a l -
te red vascu la r permeability o r even a genetically dete rmined 
Fe recep tor de fect on phagocytes as proposed by Frank et a ! 
[1 7). So rt ing ou t the ro le of eac h o f these in an individua l 
pat ient will likely prove a formidable task . 
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